A heartbreaking incident has shaken Nagpur after reports emerged on October 10, 2025, that several children admitted to a city hospital died after allegedly consuming toxic cough syrup. The syrup, believed to have been distributed through local pharmacies and smaller clinics, was found to contain harmful levels of diethylene glycol — a chemical known to cause kidney failure. Hospital sources confirmed multiple pediatric cases showing similar symptoms of poisoning, prompting the Maharashtra FDA to seal the remaining stock and begin an urgent recall. This tragedy mirrors earlier episodes of contaminated syrup deaths in India and abroad. In 2022, at least 66 children died in The Gambia after consuming Indian-manufactured cough syrup, sparking global scrutiny of drug safety standards. Similarly, in 2023, Tamil Nadu and Uttar Pradesh reported fatalities linked to spurious pediatric formulations. Despite repeated crackdowns, counterfeit or poorly regulated medicines continue to circulate through unlicensed distributors and small-scale manufacturers, exposing serious gaps in pharmaceutical oversight. Health officials in Nagpur have now launched a joint investigation involving the Food and Drug Administration (FDA), police, and the Health Department. Samples from the affected hospital have been sent to a Mumbai laboratory for testing, while the manufacturer’s license has been suspended pending results. Authorities have appealed to citizens to immediately stop using the identified brand and report any adverse reactions. Meanwhile, grief-stricken families and local activists are demanding stronger laws and stricter enforcement to prevent such tragedies from repeating. #NagpurHospital#CoughSyrupDeaths#ToxicMedicine#DrugSafety#PharmaScandal#PublicHealthCrisis#MaharashtraFDA#ChildSafety#MedicalNegligence#NagpurNews
